Cargando…

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison

Recently, several drugs have been introduced for the first-line treatment of chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), but few studies have compared treatment outcomes directly. This indirect comparison among 10 clinical trials (n = 4870 patients) retrieved from Pub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Haofeng, Chen, Jialiang, Qiu, Wenhan, Lin, Sijie, Chen, Yanxiong, Liang, Guancan, Fang, Youqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989298/ https://www.ncbi.nlm.nih.gov/pubmed/29951524 http://dx.doi.org/10.1155/2017/3941217

Ejemplares similares

Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis
por: Zheng, Haofeng, et al.
Publicado: (2017)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
por: Pu, Yeong-Shiau, et al.
Publicado: (2022)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan
por: Okumura, Hiroyuki, et al.
Publicado: (2021)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
por: Cindolo, Luca, et al.
Publicado: (2017)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
por: Fan, Liancheng, et al.
Publicado: (2018)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
por: Kim, Choung-Soo, et al.
Publicado: (2016)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
por: Yamada, Yoko, et al.
Publicado: (2016)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
por: Heath, Elisabeth, et al.
Publicado: (2019)

Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
por: Jung, Seung Il, et al.
Publicado: (2020)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
por: Zhang, Wei, et al.
Publicado: (2017)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer
por: de Liaño, A G, et al.
Publicado: (2014)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
por: Poon, Darren M.C., et al.
Publicado: (2015)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
por: Kim, Choung Soo, et al.
Publicado: (2017)

Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results
por: Kimura, Go, et al.
Publicado: (2017)

Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
por: Procopio, Giuseppe, et al.
Publicado: (2020)

(177)Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
por: Procopio, G., et al.
Publicado: (2022)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
por: Freedland, Stephen J., et al.
Publicado: (2022)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_huu9oc4qfj7qa8qb47n0o0mg5l